PLCG1 is required for AML1-ETO leukemia stem cell self-renewal

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Fusion-oncogene-induced acute myeloid leukemia (AML) presents a challenge for targeted therapies.
• Understanding the molecular mechanisms driving AML, particularly AML1-ETO (AE)-driven subtypes, is crucial for developing effective treatments.

Purpose of the Study:

• To identify novel therapeutic targets for AML, with a focus on AE-driven AML.
• To investigate the role of phospholipase C (PLC) signaling in AE-driven AML pathogenesis.

Main Methods:

• High-resolution proteomic analysis was employed to identify key molecular players in AE-driven AML.
• Genetic inactivation of PLCgamma 1 (PLCG1) in murine and human AML models.
• Pharmacologic perturbation of calcium (Ca++) signaling pathways in AML cells.

Main Results:

• Proteomic analysis revealed deregulation of PLC signaling in AE-driven AML.
• PLCG1 was identified as a direct target of the AE fusion protein, induced upon binding to regulatory DNA.
• Genetic inactivation of PLCG1 significantly inhibited AML proliferation, self-renewal, and in vivo leukemia maintenance.
• PLCG1 was found to be dispensable for normal hematopoietic stem and progenitor cell function.
• Pharmacologic inhibition of Ca++ signaling corroborated the therapeutic potential of targeting the PLCG1 pathway.

Conclusions:

• The PLCG1 pathway is a critical driver of AE-driven AML and represents a specific vulnerability.
• Targeting PLCG1 offers a promising therapeutic strategy for AML1-ETO+ leukemic stem cells, with minimal impact on normal hematopoiesis.